MedPath

Roche Holding Announces Phase 2a Results for RGT-075 and Initiates Phase 2b Study in the US

Roche Holding has released the Phase 2a topline results for RGT-075, an oral once-daily small molecule GLP-1R agonist, and has begun a Phase 2b study in the US for obesity treatment.

Roche Holding has recently announced the Phase 2a topline results for RGT-075, an innovative oral once-daily small molecule GLP-1R agonist. This development marks a significant step forward in the treatment of obesity, showcasing Roche's commitment to addressing complex health challenges. Following these promising results, the company has initiated a Phase 2b study in the United States, aiming to further evaluate the efficacy and safety of RGT-075 in a larger patient population. This progression underscores Roche's dedication to advancing medical science and providing new therapeutic options for patients worldwide.
Subscribe Icon

Stay Updated with Our Daily Newsletter

Get the latest pharmaceutical insights, research highlights, and industry updates delivered to your inbox every day.

Related Topics

Regor's Oral GLP-1RA RGT-075 Shows Promise in Phase 2a Obesity Trial

Regor Therapeutics' RGT-075, an oral GLP-1 receptor agonist, demonstrated a statistically significant 5% placebo-adjusted weight loss in obese patients.
The Phase 2a trial showed a favorable safety profile for RGT-075, with adverse event-related discontinuation rates similar to placebo.

GH Research Awaits Phase 2b Topline Data for GH001 in Treatment-Resistant Depression

GH Research anticipates topline data from its Phase 2b trial of GH001, an inhaled formulation of mebufotenin (5-MeO-DMT), for treatment-resistant depression by early 2025.
GH001 is also under evaluation in Phase 2 trials for postpartum depression and bipolar disorder type II with current depressive episodes in Europe.

Repare Therapeutics' Gynecological Cancer Trial Shows Mixed Results, Beigene Inks $1.5B Deal for MAT2A Inhibitor

Repare Therapeutics' phase I trial of lunresertib and camonsertib in gynecological cancers with specific biomarkers showed mixed results, impacting stock prices.
Beigene secured a global licensing agreement with CSPC for SYH-2039, a phase I MAT2A inhibitor targeting solid tumors, for up to $1.5 billion.

Organovo's FXR314 Demonstrates Positive Phase 2 Results in MASH Treatment

Organovo's FXR314 showed a statistically significant reduction in liver fat content compared to placebo in patients with Metabolic Dysfunction-Associated Steatohepatitis (MASH).
The Phase 2 trial demonstrated that 29.2% and 32.2% of patients receiving 3 mg and 6 mg doses of FXR314, respectively, experienced over a 30% reduction in liver fat fraction.

Shuttle Pharmaceuticals' Ropidoxuridine Shows Promise in Phase 2 Glioblastoma Trial

Shuttle Pharmaceuticals has successfully dosed the first three patients in a Phase 2 trial of ropidoxuridine for glioblastoma.
The trial is evaluating ropidoxuridine as a radiation sensitizer to enhance the effectiveness of radiation therapy.

Pharma Update: Regulatory Approvals, Clinical Data, and Strategic Moves

The FDA has approved Pfizer's Abrysvo for RSV in adults under 60 at increased risk, making it the only RSV vaccine for this age group.
Novo Nordisk's oral semaglutide (Rybelsus) demonstrated a 14% reduction in major adverse cardiovascular events in type 2 diabetes patients.

Roche Reports Strong Q3 Growth Driven by Key Pharmaceuticals and Diagnostics

Roche's Group sales increased by 6% in the first nine months of 2024, driven by high demand for both medicines and diagnostics, with a 9% rise in Q3.
Pharmaceuticals Division sales grew by 7%, propelled by strong demand for newer medicines like Vabysmo, Phesgo, and Ocrevus, which target severe diseases.

Surrozen's SZR-047 Meets Primary Endpoint in Phase III Trial for Muscle Disease

Surrozen's SZR-047 demonstrated a statistically significant improvement in muscle strength compared to placebo in the Phase III clinical trial.
The trial met its primary endpoint, indicating the drug's potential efficacy in treating the rare muscle disease.

Roche Acquires Regor Therapeutics' CDK Inhibitors for Breast Cancer Treatment

Roche has agreed to acquire two experimental breast cancer drugs, next-generation CDK inhibitors, from Regor Therapeutics for $850 million upfront.
One drug, RGT-419B, is in Phase 1 trials and has shown durable single-agent activity in patients who progressed after CDK4/6 inhibitor treatment.

Roche Unfazed by Side Effects in Early Obesity Drug Trial, Eyes 'Best-in-Class' Potential

Roche remains confident in its obesity drug candidates despite initial concerns over side effects observed in a small study of CT-388, a weight-loss shot.
The company emphasizes that no patients discontinued treatment due to side effects, which included nausea, vomiting, and diarrhea.

Reference News

[1]
Roche Holding Aktie (855167,CH0012032048) | Kurs
finanzen100.de · Jan 10, 2025

Roche Holding announced Phase 2a topline results for RGT-075, an oral GLP-1R agonist for obesity, and started a Phase 2b...

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy